CN104649901B - A kind of preparation method of the material medicine ingenol methyl butene acid esters for treating actinic keratosiss - Google Patents
A kind of preparation method of the material medicine ingenol methyl butene acid esters for treating actinic keratosiss Download PDFInfo
- Publication number
- CN104649901B CN104649901B CN201510066743.3A CN201510066743A CN104649901B CN 104649901 B CN104649901 B CN 104649901B CN 201510066743 A CN201510066743 A CN 201510066743A CN 104649901 B CN104649901 B CN 104649901B
- Authority
- CN
- China
- Prior art keywords
- silica gel
- methanol
- petroleum ether
- ingenol
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 title claims abstract description 19
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 9
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 title claims 4
- 239000002253 acid Substances 0.000 title claims 4
- 150000002148 esters Chemical class 0.000 title claims 4
- 239000003814 drug Substances 0.000 title abstract description 13
- 208000009621 actinic keratosis Diseases 0.000 title abstract description 4
- 239000000463 material Substances 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003208 petroleum Substances 0.000 claims abstract description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000741 silica gel Substances 0.000 claims abstract description 28
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000000926 separation method Methods 0.000 claims abstract description 22
- 238000000746 purification Methods 0.000 claims abstract description 21
- 239000011347 resin Substances 0.000 claims abstract description 20
- 229920005989 resin Polymers 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 150000002009 diols Chemical class 0.000 claims abstract description 16
- 229920005654 Sephadex Polymers 0.000 claims abstract description 15
- 239000012507 Sephadex™ Substances 0.000 claims abstract description 15
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 239000000499 gel Substances 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 18
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims description 14
- 229960002993 ingenol mebutate Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000178 monomer Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 125000001033 ether group Chemical group 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 229930004069 diterpene Natural products 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960001866 silicon dioxide Drugs 0.000 claims 9
- 239000004575 stone Substances 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 125000000567 diterpene group Chemical group 0.000 claims 2
- 239000000039 congener Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 241000221079 Euphorbia <genus> Species 0.000 abstract description 10
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 150000004141 diterpene derivatives Chemical class 0.000 description 7
- 240000001837 Euphorbia peplus Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MCVVUJPXSBQTRZ-ONEGZZNKSA-N methyl (e)-but-2-enoate Chemical compound COC(=O)\C=C\C MCVVUJPXSBQTRZ-ONEGZZNKSA-N 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000006257 total synthesis reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000000225 Euphorbia hirta Species 0.000 description 1
- 241000701408 Euphorbia kansui Species 0.000 description 1
- 229930185597 Euphorbia lathyris Natural products 0.000 description 1
- 241001553700 Euphorbia lathyris Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- -1 [α] 25 D +46.6 (0.25 Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940107670 picato Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/76—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
- C07C2603/84—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing rings with more than eight members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种治疗光化性角化病的原料药物巨大戟醇甲基丁烯酸酯的制备方法,包括下述步骤:原料提取、石油醚萃取、大孔树脂D101吸附干法拌样划段、硅胶分离、Sephadex凝胶纯化、DIOL硅胶纯化。该方法从南欧大戟全草植物分离原料药物巨大戟醇甲基丁烯酸酯,具备分离纯化快捷简单,高效高纯,成本较低等优点。A method for preparing a raw material drug ingenol methacrylate for treating actinic keratosis, comprising the following steps: raw material extraction, petroleum ether extraction, macroporous resin D101 adsorption dry method mixing section, silica gel Separation, Sephadex gel purification, DIOL silica gel purification. The method separates the raw drug ingenol methacrylate from the whole plant of Euphorbia euphorbia, and has the advantages of fast and simple separation and purification, high efficiency and high purity, and low cost.
Description
技术领域:Technical field:
本发明属于药物制备方法技术领域,具体地,涉及一种治疗光化性角化病原料药物巨大戟醇的制备方法。The invention belongs to the technical field of medicine preparation methods, and in particular relates to a preparation method of ingenol, a raw material medicine for treating actinic keratosis.
背景技术Background technique
2012年1月23日美国FDA批准了巨大戟醇甲基丁烯酸酯(Ingenol Mebutate),作为用于治疗光化性角化病(Actinic Keratosis,AK,对阳光敏感的一种皮肤病)药物上市。该药物的商品名Picato,由LEO Pharma AS研发成功。On January 23, 2012, the US FDA approved Ingenol Mebutate as a drug for the treatment of Actinic Keratosis (AK, a skin disease sensitive to sunlight) listed. The drug, trade name Picato, was successfully developed by LEO Pharma AS.
巨大戟醇甲基丁烯酸酯(Ingenol Mebutate),可以从大戟属植物(Euphorbia)中提取分离纯化,如Euphorbia peplus,Euphorbia hirta,Euphorbia drummondi,及中药Euphorbia lathyris(千金子),Euphorbia kansui(甘遂)等同属植物都含有该原料药物。但该原料药物含量很低,而其Ingenol Mebutate的母核骨架化合物Ingenol,同属植物中也分布很广,可供提取分离纯化。母核Ingenol为四环二萜天然产物,其中B环、C环是由环张力非常大的bicyclic[4,4,1]undecane构成,由于其桥头上的inside-outsidestereochemistry,即构成C环的C-11到C-14在桥头异侧,使其张力大增。合成化学家对此特殊立体化学现象特别感兴趣,也使得Ingenol的全合成研究成为热点,Wood,Tanino/Kuwajima,Winkler,Funk,Rigby等研究团队都完成了Ingenol的全合成研究。最便捷的Ingenol全合成仅需七步反应。使得原料药物巨大戟醇甲基丁烯酸酯(Ingenol Mebutate)可以从合成和半合成途径得到。Ingenol Mebutate can be extracted, isolated and purified from Euphorbia plants, such as Euphorbia peplus, Euphorbia hirta, Euphorbia drummondi, and traditional Chinese medicine Euphorbia lathyris (daughter of gold), Euphorbia kansui ( Gansui) and other plants of the same genus all contain the raw material medicine. However, the content of the raw drug is very low, and its Ingenol Mebutate's mother core skeleton compound Ingenol is also widely distributed in the same genus of plants, which can be used for extraction, separation and purification. The mother core Ingenol is a tetracyclic diterpene natural product, in which the B ring and C ring are composed of bicyclic[4,4,1]undecane with very large ring tension, due to the inside-outsidestereochemistry on the bridgehead, that is, the C -11 to C-14 are on the opposite side of the bridgehead, greatly increasing its tension. Synthetic chemists are particularly interested in this special stereochemical phenomenon, which also makes the total synthesis of Ingenol a hot spot. Wood, Tanino/Kuwajima, Winkler, Funk, Rigby and other research teams have completed the total synthesis of Ingenol. The most convenient total synthesis of Ingenol requires only seven steps. The raw material drug Ingenol Mebutate can be obtained from synthetic and semi-synthetic routes.
南欧大戟(Euphorbia peplus Linn),原产地中海沿岸(南欧至北非),归化于亚洲、美洲和澳大利亚;我国的台湾(台北、台中)、广东、香港、福建(厦门、福州)、广西(南宁)和云南(昆明)相继发现归化植株或种群,作为大戟属植物的一种,南欧大戟在云南省已经广泛分布,田边地头,园林绿化区域,随处可见,因其乳汁具有毒性,不能作为牧草,资源极大,是巨大戟醇甲基丁烯酸酯的原料资源基础。Southern European euphorbia (Euphorbia peplus Linn), native to the Mediterranean coast (Southern Europe to North Africa), naturalized in Asia, America and Australia; my country's Taiwan (Taipei, Taichung), Guangdong, Hong Kong, Fujian (Xiamen, Fuzhou), Guangxi ( Nanning) and Yunnan (Kunming) successively found naturalized plants or populations. As a kind of Euphorbia plant, Southern European Euphorbia has been widely distributed in Yunnan Province. It can be seen everywhere in fields and landscaping areas, because its milk is toxic. , can not be used as pasture, the resources are huge, and it is the raw material resource base of ingenol methacrylate.
迄今为止,现有技术中未见有从南欧大戟中提取巨大戟醇甲基丁烯酸酯工业药物原料的工艺方法的报道。So far, there is no report on the process of extracting ingenol methacrylate industrial pharmaceutical raw material from Euphorbia euphorbia in the prior art.
发明内容Contents of the invention
本发明的目的在于提供一种从广布云南地区的外来植物南欧大戟(Euphorbiapeplus) 中提取分离纯化天然原料药物巨大戟醇甲基丁烯酸酯(Ingenol Mebutate)的方法。该工艺方法具备分离纯化快捷简单,高效高纯,成本较低等优点。The object of the present invention is to provide a method for extracting, separating and purifying natural raw material drug Ingenol Mebutate from the exotic plant Euphorbiapeplus widely distributed in Yunnan area. The process method has the advantages of fast and simple separation and purification, high efficiency and high purity, and low cost.
为了实现本发明的上述目的,本发明提供了如下的技术方案:In order to realize the above-mentioned purpose of the present invention, the present invention provides following technical scheme:
巨大戟醇甲基丁烯酸酯的制备方法,包括下述步骤:原料提取、石油醚萃取、大孔树脂D101吸附干法拌样划段、硅胶分离、Sephadex凝胶纯化、DIOL硅胶纯化;The preparation method of ingenol methyl crotonate comprises the following steps: raw material extraction, petroleum ether extraction, macroporous resin D101 adsorption dry method sample mixing section, silica gel separation, Sephadex gel purification, DIOL silica gel purification;
所述的原料提取为:采集各地的南欧大戟或同属植物全草,在自然阳光下晾晒干燥,切碎后以甲醇浸泡,加热回流提取三次,过滤除去残渣,滤液浓缩后得总浸膏;The extraction of the raw materials is as follows: collect Euphorbia euphorbia or the whole plant of the same genus from various places, dry it in the sun under natural sunlight, soak it in methanol after chopping, heat and reflux for extraction three times, filter to remove the residue, and obtain the total extract after concentrating the filtrate;
所述的石油醚萃取为:总浸膏水混悬分散后,以体积比1:1石油醚萃取3次,分液浓缩石油醚部分,得石油醚总浸膏;The petroleum ether extraction is as follows: after the total extract is suspended and dispersed in water, it is extracted 3 times with petroleum ether at a volume ratio of 1:1, and the petroleum ether part is separated and concentrated to obtain the total extract of petroleum ether;
所述的大孔树脂D101吸附干法拌样划段是用石油醚总浸膏,用适量氯仿溶解,与大孔树脂D101干法拌样,然后用大孔树脂柱粗分离,以甲醇/水溶液作为流动相,按40%、60%、80%、100%洗脱,收集80%甲醇水溶液洗脱洗脱流份,减压浓缩回收溶液,得到浸膏为总二萜部位;The section of the macroporous resin D101 adsorption dry sample mixing is to use the total extract of petroleum ether, dissolve it with an appropriate amount of chloroform, mix the sample with the macroporous resin D101 dry method, and then roughly separate it with a macroporous resin column, and use methanol/water solution As the mobile phase, elute at 40%, 60%, 80%, and 100%, collect 80% methanol aqueous solution to elute the eluted fraction, concentrate and recover the solution under reduced pressure, and obtain the extract as the total diterpene fraction;
所述硅胶分离为:以适量氯仿溶解后硅胶拌样,装硅胶柱粗分离,用石油醚/乙酸乙酯作为洗脱液进行梯度洗脱,得到8个主要部位Fr I-VIII,其中Fr VII以C18柱分离,再得10个亚部位subFr1-10;The silica gel separation is as follows: the silica gel sample is mixed with an appropriate amount of chloroform, the silica gel column is installed for rough separation, and petroleum ether/ethyl acetate is used as the eluent for gradient elution to obtain 8 main parts Fr I-VIII, wherein Fr VII Separation with C18 column to obtain 10 sub-parts subFr1-10;
所述Sephadex凝胶纯化为:对亚部位subFr8-9,再上Sephadex凝胶柱用甲醇洗脱,收集流份浓缩,得到目标化合物单体;The Sephadex gel purification is as follows: for the sub-site subFr8-9, and then eluted with methanol on the Sephadex gel column, the collected fractions are concentrated, and the target compound monomer is obtained;
所述DIOL硅胶纯化为:得到单体化合物,经DIOL硅胶再次分离纯化,得到纯度98%以上巨大戟醇甲基丁烯酸酯。The DIOL silica gel purification is as follows: the monomer compound is obtained, which is separated and purified again by DIOL silica gel to obtain ingenol methacrylate with a purity of more than 98%.
如所述的巨大戟醇甲基丁烯酸酯的制备方法,其中所述的方法关键步骤为大孔树脂D101吸附拌样划段得到总二萜部位;Sephadex凝胶柱层析纯化得到化合物单体;DIOL硅胶柱层析纯化得到高纯目标原料单体。As described in the preparation method of ingenol methyl crotonate, wherein the key step of the method is to obtain the total diterpene parts by adsorption and mixing of macroporous resin D101; Sephadex gel column chromatography purification to obtain the compound single body; purified by DIOL silica gel column chromatography to obtain high-purity target raw material monomer.
如所述的巨大戟醇甲基丁烯酸酯的制备方法,其中所述的方法为取南欧大戟全草,干燥,切碎后以甲醇浸泡,加热回流提取三次,过滤除去残渣,滤液浓缩后得总浸膏,浸膏以20L水混悬分散后,体积比1:1石油醚萃取5次,浓缩石油醚部分,得石油醚总浸膏,以适量氯仿溶解浸膏,用大孔树脂D101干法拌样,然后用大孔树脂柱粗分离,以甲醇/水溶液作为流动相,按40%、60%、80%、100%洗脱;对80%甲醇洗脱液浓缩回收得总二萜部位,以适量氯仿溶解后硅胶200~300目拌样,装硅胶柱粗分离,以20:1-0:1 的石油醚:乙酸乙酯进行梯度洗脱,得到8个主要部位Fr I-VIII,其中Fr VII以C18柱分离,得10个亚部位subFr1-10,subFr9再上sephadex凝胶柱用甲醇洗脱,得到纯度90%以上的目标化合物,再次经DIOL分离纯化,得到纯度98%以上的巨大戟醇甲基丁烯酸酯Ingenol Mebutate。The preparation method of ingenol methyl crotonate as described above, wherein the method is to take the whole plant of Euphorbia euphorbia, dry it, chop it, soak it in methanol, extract it under reflux for three times, filter to remove the residue, and concentrate the filtrate Finally, the total extract was obtained. After the extract was suspended and dispersed in 20L of water, it was extracted 5 times with petroleum ether at a volume ratio of 1:1, and the petroleum ether part was concentrated to obtain the total extract of petroleum ether. D101 dry mixed sample, then roughly separated with a macroporous resin column, using methanol/water solution as mobile phase, and eluted at 40%, 60%, 80%, 100%; 80% methanol eluate was concentrated and recovered to obtain total two For the terpene part, after dissolving with an appropriate amount of chloroform, mix the sample with 200-300 mesh silica gel, install a silica gel column for rough separation, and perform gradient elution with 20:1-0:1 petroleum ether: ethyl acetate to obtain 8 main parts Fr I- VIII, wherein Fr VII was separated by C18 column to obtain 10 sub-parts subFr1-10, and subFr9 was eluted with methanol on a sephadex gel column to obtain the target compound with a purity of more than 90%, which was separated and purified by DIOL again to obtain a purity of 98%. Ingenol Mebutate above.
具体实施方式detailed description
下面用本发明的实施例来进一步说明本发明的实质性内容,但并不以此来限定本发明。The following examples of the present invention are used to further illustrate the substantive content of the present invention, but the present invention is not limited thereto.
实施例1Example 1
Ingenol Mebutate的制备:Preparation of Ingenol Mebutate:
1.原料甲醇提取:采集各地的南欧大戟(Euphorbia peplus Linn)或同属植物全草,在自然阳光下晾晒干燥,切碎后以甲醇浸泡,加热回流提取三次,过滤除去残渣,滤液浓缩后得总浸膏。1. Methanol extraction of raw materials: Collect Euphorbia peplus Linn or the whole plant of the same genus from various places, dry it in the sun, chop it, soak it in methanol, extract it under reflux for three times, filter to remove the residue, and concentrate the filtrate to obtain total extract.
2.石油醚萃取:总浸膏水混悬分散后,以体积比1:1石油醚萃取3次,分液浓缩石油醚部分,得石油醚总浸膏。2. Petroleum ether extraction: After the total extract was suspended and dispersed in water, it was extracted 3 times with petroleum ether at a volume ratio of 1:1, and the petroleum ether part was concentrated by liquid separation to obtain the total extract of petroleum ether.
3.大孔树脂D101吸附干法拌样划段:石油醚总浸膏用适量氯仿溶解,与大孔树脂D101干法拌样,然后用大孔树脂柱粗分离,以甲醇/水溶液作为流动相,按40%、60%、80%、100%洗脱。收集80%甲醇水溶液洗脱洗脱流份,减压浓缩回收溶液,得到浸膏为总二萜部位。3. Macroporous resin D101 adsorption dry sample mixing section: the petroleum ether total extract is dissolved in an appropriate amount of chloroform, mixed with macroporous resin D101 dry method, and then roughly separated by a macroporous resin column, using methanol/water solution as the mobile phase , according to 40%, 60%, 80%, 100% elution. Collect 80% methanol aqueous solution to elute the eluted fraction, concentrate and recover the solution under reduced pressure, and obtain the extract as the total diterpene fraction.
4.硅胶分离:以适量氯仿溶解后硅胶拌样,装硅胶柱粗分离,用石油醚/乙酸乙酯作为洗脱液进行梯度洗脱,得到8个主要部位(Fr I-VIII),其中Fr VII以C18(FujiSilysia Chemical公司)柱分离,再得10个亚部位subFr1-10。目标化合物主要在subFr8-9。4. Silica gel separation: mix the sample with silica gel after dissolving an appropriate amount of chloroform, install a silica gel column for rough separation, and use petroleum ether/ethyl acetate as the eluent for gradient elution to obtain 8 main parts (Fr I-VIII), of which Fr VII was separated on a C18 (FujiSilysia Chemical Company) column to obtain 10 subparts subFr1-10. The target compounds are mainly in subFr8-9.
5.Sephadex凝胶纯化:对亚部位subFr8-9,再上Sephadex凝胶柱用甲醇洗脱,收集流份浓缩,得到目标化合物单体。5. Sephadex gel purification: for the sub-site subFr8-9, and then eluted with methanol on a Sephadex gel column, the collected fractions were concentrated to obtain the target compound monomer.
6.DIOL硅胶纯化:得到单体化合物,经DIOL硅胶再次分离纯化,得到纯度98%以上巨大戟醇甲基丁烯酸酯(Ingenol Mebutate)。6. Purification on DIOL silica gel: the monomer compound was obtained, and separated and purified again by DIOL silica gel to obtain Ingenol Mebutate with a purity of more than 98%.
上述方法的关键点在于:The key points of the above method are:
1.大孔树脂D101吸附拌样划段得到总二萜部位;1. Macroporous resin D101 absorbs and mixes samples to obtain total diterpene parts;
2.Sephadex凝胶纯化得到化合物单体;2. Sephadex gel purification to obtain the compound monomer;
3.DIOL硅胶纯化得到高纯目标原料单体。3. DIOL silica gel purification to obtain high-purity target raw material monomer.
实施例2Example 2
巨大戟醇甲基丁烯酸酯(Ingenol Mebutate)的制备:Preparation of Ingenol Mebutate:
从南欧大戟全草植物分离原料药物巨大戟醇甲基丁烯酸酯:Isolation of raw material drug ingenol methacrylate from whole plant of Euphorbia euphorbia:
南欧大戟(Euphorbia peplus Linn)采集于昆明北郊,干燥全草20kg,切碎后以甲醇浸泡,加热回流提取三次(3×100L),过滤除去残渣,滤液浓缩后得总浸膏约6kg,浸膏以20L水混悬分散后,体积比1:1石油醚萃取5次,浓缩石油醚部分,得石油醚总浸膏4kg,以适量氯仿溶解浸膏,用大孔树脂D101(天津市海光化工有限公司)干法拌样,然后用大孔树脂柱粗分离,以甲醇/水溶液作为流动相,按40%、60%、80%、100%洗脱。对80%甲醇洗脱液浓缩回收得总二萜部位300g,以适量氯仿溶解后硅胶(200~300目)拌样,装硅胶柱粗分离,以石油醚:乙酸乙酯(20:1-0:1)进行梯度洗脱,得到8个主要部位(Fr I-VIII),其中Fr VII以C18(Fuji Silysia Chemical公司)柱分离,得10个亚部位subFr1-10,subFr9再上sephadex凝胶柱用甲醇洗脱,得到目标化合物(106mg),纯度90%以上。再次经DIOL(FujiSilysia Chemical公司)分离纯化,得到巨大戟醇甲基丁烯酸酯(Ingenol Mebutate)(95mg),纯度98%以上,得率百万分之4.75%。Euphorbia peplus Linn was collected in the northern suburbs of Kunming, dried whole herb 20kg, chopped, soaked in methanol, heated and refluxed for three times (3×100L), filtered to remove the residue, and the filtrate was concentrated to obtain a total extract of about 6kg. After the extract was suspended and dispersed in 20L of water, it was extracted 5 times with petroleum ether at a volume ratio of 1:1, and the petroleum ether part was concentrated to obtain 4kg of total petroleum ether extract. Chemical Co., Ltd.) dry-mixed sample, and then roughly separated with a macroporous resin column, using methanol/water solution as the mobile phase, and eluted by 40%, 60%, 80%, and 100%. Concentrate and recover the 80% methanol eluent to obtain 300 g of total diterpene parts, dissolve with an appropriate amount of chloroform, mix the sample with silica gel (200-300 mesh), install a silica gel column for rough separation, and use petroleum ether: ethyl acetate (20:1-0 : 1) Carry out gradient elution to obtain 8 main parts (Fr I-VIII), wherein Fr VII is separated by C18 (Fuji Silysia Chemical Company) column, and 10 sub-parts subFr1-10 are obtained, and subFr9 is put on a sephadex gel column Eluted with methanol, the target compound (106 mg) was obtained with a purity of over 90%. Separation and purification by DIOL (FujiSilysia Chemical Company) again gave Ingenol Mebutate (95 mg) with a purity of over 98% and a yield of 4.75 parts per million.
Ingenol Mebutate的化学结构表征:Chemical structure characterization of Ingenol Mebutate:
Ingenol Mebutate,无定型粉末(amorphous powder),[α]25 D+46.6(0.25,MeOH)。其波谱数据为:Ingenol Mebutate, amorphous powder, [α] 25 D +46.6 (0.25, MeOH). Its spectral data are:
紫外光谱UV(MeOH)λmax(logε):203(4.03)nm;Ultraviolet spectrum UV (MeOH) λ max (log ε): 203 (4.03) nm;
红外光谱IR(KBr)υmax:3434,2928,1715,1457,1382,1231,1156,1040cm-1;Infrared spectrum IR (KBr) υ max : 3434, 2928, 1715, 1457, 1382, 1231, 1156, 1040cm -1 ;
氢谱1H NMR(600MHz,CDCl3)δ:5.99(1H,m,H-1),5.57(1H,s,H-3),4.01(1H,s,H-5),6.00(1H,m,H-7),4.14(1H,m,H-8),0.88(1H,dd,J=11.7,8.5Hz,H-9),0.65(1H,dd,J=15.1,8.6Hz,H-11),2.24(1H,m,H-12),1.70(1H,m,H-12),2.52(1H,m,H-13),1.75(3H,brs,H-16),4.09(2H,m,H-17),1.01(3H,s,H-18),1.04(3H,s,H-19),0.93(3H,d,J=7.1Hz,H-20),6.11(1H,tt,J=7.3,3.6Hz,H-3’),1.97(3H,dd,J=7.2,1.2Hz,H-4’),1.88(3H,m,H-5’);Hydrogen spectrum 1 H NMR (600MHz, CDCl 3 ) δ: 5.99(1H,m,H-1),5.57(1H,s,H-3),4.01(1H,s,H-5),6.00(1H, m, H-7), 4.14 (1H, m, H-8), 0.88 (1H, dd, J=11.7, 8.5Hz, H-9), 0.65 (1H, dd, J=15.1, 8.6Hz, H -11),2.24(1H,m,H-12),1.70(1H,m,H-12),2.52(1H,m,H-13),1.75(3H,brs,H-16),4.09( 2H,m,H-17),1.01(3H,s,H-18),1.04(3H,s,H-19),0.93(3H,d,J=7.1Hz,H-20),6.11(1H ,tt,J=7.3,3.6Hz,H-3'),1.97(3H,dd,J=7.2,1.2Hz,H-4'),1.88(3H,m,H-5');
碳谱13C NMR(150MHz,CDCl3)δ:131.9(C-1),135.9(C-2),82.4(C-3),84.9(C-4),76.1(C-5),139.5(C-6),128.1(C-7),43.4(C-8),22.8(C-9),24.0(C-10),23.2(C-11),30.9(C-12),38.3(C-13),207.4(C-14),71.9(C-15),15.5(C-16),66.9(C-16),28.4(C-18),15.5(C-19),17.1(C-20),168.6(C-1’),127.3(C-2’),139.4(C-3’),15.9(C-4’),20.8(C-5’)。Carbon Spectrum 13 C NMR (150MHz, CDCl 3 ) δ: 131.9(C-1), 135.9(C-2), 82.4(C-3), 84.9(C-4), 76.1(C-5), 139.5( C-6), 128.1(C-7), 43.4(C-8), 22.8(C-9), 24.0(C-10), 23.2(C-11), 30.9(C-12), 38.3(C -13), 207.4(C-14), 71.9(C-15), 15.5(C-16), 66.9(C-16), 28.4(C-18), 15.5(C-19), 17.1(C- 20), 168.6 (C-1'), 127.3 (C-2'), 139.4 (C-3'), 15.9 (C-4'), 20.8 (C-5').
与现有技术相比,本发明的工艺方法有如下的优益性:1)大孔树脂D101直接吸附拌样划段得到总二萜部位,与常规的溶剂溶解湿法上大孔树脂D101柱层析样品不同;2)Sephadex凝胶柱层析纯化得到化合物单体;3)DIOL硅胶柱层析纯化得到高纯目标原料单体,将DIOL硅胶柱层析高效纯化用于工业药物原料的纯化未见报道。该工艺方法具备分离纯化快捷简单,高效高纯,成本较低等优点。Compared with the prior art, the process method of the present invention has the following advantages: 1) The macroporous resin D101 directly absorbs and mixes the samples and divides to obtain the total diterpene parts, and the macroporous resin D101 column on the conventional solvent-dissolved wet method Chromatographic samples are different; 2) Sephadex gel column chromatography purification to obtain compound monomers; 3) DIOL silica gel column chromatography purification to obtain high-purity target raw material monomers, and DIOL silica gel column chromatography for efficient purification of industrial pharmaceutical raw materials None reported. The process method has the advantages of fast and simple separation and purification, high efficiency and high purity, and low cost.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510066743.3A CN104649901B (en) | 2015-02-09 | 2015-02-09 | A kind of preparation method of the material medicine ingenol methyl butene acid esters for treating actinic keratosiss |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510066743.3A CN104649901B (en) | 2015-02-09 | 2015-02-09 | A kind of preparation method of the material medicine ingenol methyl butene acid esters for treating actinic keratosiss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104649901A CN104649901A (en) | 2015-05-27 |
| CN104649901B true CN104649901B (en) | 2017-03-29 |
Family
ID=53241608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510066743.3A Active CN104649901B (en) | 2015-02-09 | 2015-02-09 | A kind of preparation method of the material medicine ingenol methyl butene acid esters for treating actinic keratosiss |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104649901B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105152889A (en) * | 2015-08-19 | 2015-12-16 | 西安岳达植物科技有限公司 | Extraction method of ingenol |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ801700A0 (en) * | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| SI2595948T1 (en) * | 2010-07-20 | 2019-12-31 | Leo Laboratories Limited | A method of producing ingenol-3-angelate |
-
2015
- 2015-02-09 CN CN201510066743.3A patent/CN104649901B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104649901A (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104327127B (en) | Method for preparing angroside C, aucubin and harpagide through separation and purification by high-speed countercurrent chromatography | |
| EP2650301B1 (en) | Method for preparing albiflorin and paeoniflorin | |
| CN107304213B (en) | Method and equipment for processing poppy extract | |
| CN101863935B (en) | Preparation method of 1,4-di-[4-(glucosyloxy) benzyl]-2-isobutyl malate comparison product | |
| CN102372754A (en) | Method for preparing specnuezhenide | |
| CN102924537B (en) | Method for preparing hyperoside and isoquercitrin simultaneously from dogbane leaves | |
| CN100422191C (en) | The method for separating and preparing triptolide diol from tripterygium wilfordii | |
| CN101941961B (en) | Method for extracting and separating kaempferol from impatiens balsamina | |
| CN104649901B (en) | A kind of preparation method of the material medicine ingenol methyl butene acid esters for treating actinic keratosiss | |
| CN106496292A (en) | A kind of method for preparing 6 iridoid glycoside constituents from Fructus Gardeniae simultaneously | |
| CN106008445A (en) | Flavone and lignin compound and extracting method thereof | |
| CN105061212B (en) | A kind of preparation method of neochlorogenic acid | |
| CN109553618A (en) | A kind of extracting method of matrine | |
| CN102391328B (en) | Method for simultaneously preparing chemical reference substances magnoloside A and magnoloside B | |
| CN104370814B (en) | A method for extracting sea papaverine from bundled fairy rope | |
| CN102093454B (en) | Preparation method of alisol C monoacetic ester | |
| CN101085794B (en) | Method for preparing 10-deacetyl asperulosidic acid methyl ester | |
| CN105016982A (en) | Method for extracting, separating and purifying honokiol and magnolol from magnolia officinalis | |
| CN111233629A (en) | Method for preparing compound BZ-92 from traditional Chinese medicine bighead atractylodes rhizome | |
| CN114349808B (en) | Separation and purification method of rabdosia amethystoides saponin A and B monomers and application thereof | |
| CN1318438C (en) | Method for preparing tanning material bonducin | |
| CN103601788A (en) | Method of extracting and separating triterpenoid ellagitannin compound from castanopsis fissa leaves | |
| CN101863882B (en) | A kind of method of separating and purifying piperonoid B | |
| CN106188178A (en) | A kind of method preparing protodioscin | |
| CN111704640B (en) | Method for preparing citrusin from Uncaria chinensis by high-speed countercurrent chromatography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| OL01 | Intention to license declared | ||
| OL01 | Intention to license declared |